000170019 001__ 170019
000170019 005__ 20260316092629.0
000170019 0247_ $$2doi$$a10.1177/17588359261421813
000170019 0248_ $$2sideral$$a148509
000170019 037__ $$aART-2026-148509
000170019 041__ $$aeng
000170019 100__ $$aLópez-Tarruella, Sara
000170019 245__ $$aClinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM)
000170019 260__ $$c2026
000170019 5060_ $$aAccess copy available to the general public$$fUnrestricted
000170019 5203_ $$aBackground:
Breast cancer frequently results in brain metastases (BCBM), leading to poor outcomes. Central nervous system (CNS) involvement entails significant challenges in advanced breast cancer (ABC) patients.
Objectives:
To characterize BCBM patients according to surrogate clinical BC subtypes and evaluate the interval between ABC and BCBM detection, both at ABC diagnosis (BCBM1 cohort) and for those who develop BCBM subsequently (BCBM2 cohort). Secondary objectives included analyzing the time-related outcomes by BC subtype.
Design:
RegistEM is an ongoing ambispective, observational study of ABC patients diagnosed since January/2016.
Methods:
We describe the characteristics of BCBM patients reported by January 22, 2024, categorized by BC subtype on the most recent tumor sample obtained before first-line therapy.
Results:
At the cutoff date, 346/1947 (18%) patients diagnosed with ABC between January/2016 and December/2019 developed BCBM, and 288/346 (83%) died. All patients were female, predominantly Caucasian (98%), with a median age of 55 years at ABC diagnosis. The distribution by subtype was 170/346 (49%) HR+/HER2−, 68/346 (20%) HR+/HER2+, 54/346 (16%) HR−/HER2+, and 51/346 (15%) HR−/HER2− (triple negative (TN)). One-fourth (85/346) were in the BCBM1 cohort, with 22/85 (26%) having BCBM as the only metastatic location; in this cohort, median time to BCBM was 38 months, with shorter intervals in HR−/HER2+ and TN subtypes (17 and 18 months, respectively). In the BCBM2 cohort (261/346), the median time to BCBM was 24 months, with the shortest interval in TN (13 months). Median survival from BCBM diagnosis was 26 months (95% confidence interval (CI), 20−35) in BCBM1 and 9 months (95% CI, 7−12) in BCBM2 (hazard ratio, 2.3; 95% CI, 1.7−3.0); TN subtype showed the poorest results (median of 6 months; 95% CI, 3−13).
Conclusion:
TN and HER2+ BC subtypes progressed faster to BCBM and had worse outcomes. Survival differed significantly between the two cohorts, BCBM1 and BCBM2. Continued research is essential to improve the treatment and prevention strategies.
000170019 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttps://creativecommons.org/licenses/by-nc/4.0/deed.es
000170019 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000170019 700__ $$aGuerrero-Zotano, Ángel
000170019 700__ $$aAntolín, Silvia
000170019 700__ $$aCruz, Josefina
000170019 700__ $$aMartínez, Purificación
000170019 700__ $$aRodríguez, César A.
000170019 700__ $$aFalo, Catalina
000170019 700__ $$aRodríguez-Lescure, Álvaro
000170019 700__ $$aAdrover, Encarna
000170019 700__ $$aHernández, María
000170019 700__ $$0(orcid)0000-0003-0123-4274$$aAndrés, Raquel$$uUniversidad de Zaragoza
000170019 700__ $$aChacón, José Ignacio
000170019 700__ $$aAlonso Romero, José Luis
000170019 700__ $$aMiguel, Ana
000170019 700__ $$aGómez-Raposo, César
000170019 700__ $$aMargelí, Mireia
000170019 700__ $$aGonzález, Iria
000170019 700__ $$aGuerra, Juan Antonio
000170019 700__ $$0(orcid)0000-0002-9159-4988$$aAntón, Antonio$$uUniversidad de Zaragoza
000170019 700__ $$aTibau, Ariadna
000170019 700__ $$aMiralles, Juan José
000170019 700__ $$aEscudero, María José
000170019 700__ $$aBezares, Susana
000170019 700__ $$aRojo, Federico
000170019 700__ $$aÁlvarez, Isabel
000170019 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000170019 773__ $$g18 (2026), [22 pp.]$$pTher. adv. med. oncol.$$tTherapeutic Advances in Medical Oncology$$x1758-8340
000170019 8564_ $$s793481$$uhttps://zaguan.unizar.es/record/170019/files/texto_completo.pdf$$yVersión publicada
000170019 8564_ $$s2849295$$uhttps://zaguan.unizar.es/record/170019/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000170019 909CO $$ooai:zaguan.unizar.es:170019$$particulos$$pdriver
000170019 951__ $$a2026-03-16-08:16:56
000170019 980__ $$aARTICLE